Navigation Links
Piggy-backing proteins ride white blood cells to wipe out metastasizing cancer
Date:1/6/2014

ITHACA, N.Y. Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream lethal invaders that are linked to almost all cancer deaths by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

"These circulating cancer cells are doomed," said Michael King, Cornell professor of biomedical engineering and the study's senior author. "About 90 percent of cancer deaths are related to metastases, but now we've found a way to dispatch an army of killer white blood cells that cause apoptosis the cancer cell's own death obliterating them from the bloodstream. When surrounded by these guys, it becomes nearly impossible for the cancer cell to escape."

Metastasis is the spread of a cancer cells to other parts of the body. Surgery and radiation are effective at treating primary tumors, but difficulty in detecting metastatic cancer cells has made treatment of the spreading cancers problematic, say the scientists.

King and his colleagues injected human blood samples, and later mice, with two proteins: E-selectin (an adhesive) and TRAIL (Tumor Necrosis Factor Related Apoptosis-Inducing Ligand). The TRAIL protein joined with the E-selectin protein was able to stick to leukocytes white blood cells abundant in the bloodstream. When a cancer cell comes into contact with TRAIL, which is nearly unavoidable in the frenzied flow of blood, the cancer cell essentially kills itself.

"The mechanism is surprising and unexpected in that this repurposing of white blood cells in flowing blood is more effective than directly targeting the cancer cells with liposomes or soluble protein," say the authors.

In the laboratory, King and his colleagues tested this concept's efficacy.

When treating cancer cells with the proteins in saline, they found a 60 percent success rate in killing the cancer cells. In normal laboratory conditions, the saline lacks white blood cells to serve as a carrier for the adhesive and killer proteins. Once the proteins were added to flowing blood that mimicked human-body conditions, however, the success rate in killing the cancer cells jumped to nearly 100 percent.

The study, "TRAIL-Coated Leukocytes that Kill Cancer Cells in the Circulation," was published online today in the journal Proceedings of the National Academy of Sciences.


'/>"/>

Contact: Melissa Osgood
mmo59@cornell.edu
607-255-2059
Cornell University
Source:Eurekalert

Related biology technology :

1. The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
2. Multipotent Stem Cell Proteins Support Soft Tissue Regeneration
3. Multipotent Stem Cell Proteins Support Rejuvenation While Inhibiting Skin Cancer
4. Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Strategy
5. Chemists develop innovative nano-sensors for multiple proteins
6. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
7. Tenfold boost in ability to pinpoint proteins in cancer cells
8. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
9. Intrinsically disordered proteins: A conversation with Rohit Pappu
10. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
11. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):